Roche (RHHBY) said that U.S. President Donald Trump’s executive order aimed at lowering prescription drug prices threatens the company’s planned $50B investment in the U.S., Reuters’ Maggie Fick reports. “Should the proposed EO (Executive Order) go into effect, Roche’s ability to fund the significant investments previously announced in the U.S. will be in question,” the company said, according to Reuters.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- U.S. biotech companies debate relocating trials outside U.S., Reuters reports
- Trump’s drug-price crackdown may lead to minor concessions, WSJ reports
- Genentech announces final overall survival results from APHINITY study
- JPMorgan sees ‘most favored nation’ drug order facing ‘significant push back’
- Drink and Drug Firms Boost U.S. Manufacturing Health With $1B Plus Investment Plans